Tissue Regenix signed an exclusive distribution agreement with Joint Operations for the distribution of the OrthoPure XT product in the United Kingdom.
The initial agreement is for three years, subject to annual purchase minimums, and Joint Operations will add OrthoPure XT to its portfolio of products.
OrthoPure XT decellularized xenograft ligament utilizes Tissue Regenix’s patented dCELL technology and is reported to be the only non-human biologic graft for certain ACL reconstruction procedures available on the market. OrthoPure XT can also be used in the reconstruction of other knee ligaments, including multi-ligament and primary procedures when an autograft is not an option.
Daniel Lee, Chief Executive Officer of Tissue Regenix, said, “We are excited to partner with Joint Operations, who are experts in the distribution of orthopaedic equipment within the U.K. where an estimated 30,000 ACL surgeries take place each year1. This strategic partnership will continue our reach into the U.K., ensuring these markets have access to our pioneering medical technology, which will help to transform patient care.”
Tissue Regenix signed an exclusive distribution agreement with Joint Operations for the distribution of the OrthoPure XT product in the United Kingdom.
The initial agreement is for three years, subject to annual purchase minimums, and Joint Operations will add OrthoPure XT to its portfolio of products.
OrthoPure XT decellularized xenograft...
Tissue Regenix signed an exclusive distribution agreement with Joint Operations for the distribution of the OrthoPure XT product in the United Kingdom.
The initial agreement is for three years, subject to annual purchase minimums, and Joint Operations will add OrthoPure XT to its portfolio of products.
OrthoPure XT decellularized xenograft ligament utilizes Tissue Regenix’s patented dCELL technology and is reported to be the only non-human biologic graft for certain ACL reconstruction procedures available on the market. OrthoPure XT can also be used in the reconstruction of other knee ligaments, including multi-ligament and primary procedures when an autograft is not an option.
Daniel Lee, Chief Executive Officer of Tissue Regenix, said, “We are excited to partner with Joint Operations, who are experts in the distribution of orthopaedic equipment within the U.K. where an estimated 30,000 ACL surgeries take place each year1. This strategic partnership will continue our reach into the U.K., ensuring these markets have access to our pioneering medical technology, which will help to transform patient care.”
Copy to clipboard 
